Monday, July 1, 2013

REP 9AC Plus Interferon Clears Hepatitis B and Generates Surface Antibodies

REP 9AC is the much-anticipated new hepatitis B drug that within weeks suppresses the hepatitis B virus, enabling patients to lose the hepatitis B surface antigensomething no other drug has been able to do. In this latest study, when interferon was added to REP 9AC, patients even developed surface antibodiesessentially permanently getting rid of the infection.

—Christine. M. Kukka, Project Manager, HBV Advocate

Source: "Short Term Immunotherapy Following REP 9AC..." by Al-Mahtab, Bazinet and Vaillant. Asian Pacific Association for the Study of Liver Disease 2013 & 15th annual TIDES meeting.

Read more.....

2 comments:

  1. when will this be available in the market?

    ReplyDelete
    Replies
    1. It's still in clinical trials, but I'm hoping more information and new clinical trial results will be published next month during the AASLD (international liver meeting) conference in Washington DC.

      Delete